Clinical trials: Pancreatic Metastatic Cancer
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Neuroendocrine Tumors
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal…
- Trial name
- NCT03279601
- Testing
- Capecitabine, Dacarbazine, Capecitabine, Temozolomide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Peking University
Metastatic Pancreatic Cancer
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
- Trial name
- NCT06199466
- Testing
- Gemcitabine, Nab-paclitaxel, YL-13027
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Overall Survival
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug of Anlotinib (a small molecular anti-VEGF TKI) with PD-1 inhibitor in second-line therapy with the goal of…
- Trial name
- NCT05218629
- Testing
- Anlotinib, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Adenocarcinoma
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled…
- Trial name
- PANC-001 (NCT04270929)
- Testing
- FOLFIRI, FOLFIRINOX, TriSalus Infusion System
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Metastatic Pancreatic Cancer
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients…
- Trial name
- NCT06532331
- Testing
- ONO-7475, ONO-4538, Nab-paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
The purpose of this study was to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT04935359
- Testing
- NIS793, Nab-paclitaxel, Gemcitabine
- Where
- 113 sites in United States, Australia and 25 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Cancer
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine…
- Trial name
- NCT00652054
- Testing
- S-1
- Volunteers
- 39 people
- Sponsor
- Taiho Oncology, Inc.
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
The goal of this clinical trial is to learn if drug DZ-002 works to treat adults with metastatic pancreatic adenocarcinoma. It will also learn about the safety of drug DZ-002.
- Trial name
- DZ-002-201 (NCT07344220)
- Testing
- DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases
Combining retrospective observational research with artificial intelligence data engineering. Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts…
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07713823
- Volunteers
- 3,000 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
Minocycline Study in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if minocycline can reduce the side effects of chemotherapy in patients with pancreatic cancer. In this study, minocycline will be compared to a placebo.
- Trial name
- NCT01693523
- Testing
- Minocycline, Questionnaires
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Pancreatic Ductal, Prognosis
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1).
- Trial name
- PACsign (NCT05475366)
- Testing
- Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies)
- Where
- 7 sites in France
- Volunteers
- 79 people
- Sponsor
- Institut Curie
Pancreatic Neoplasms
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
- Trial name
- SPTP (NCT06914674)
- Testing
- Tamoxifen 20 mg
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Metastatic Pancreatic Cancer
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle.
- Trial name
- NCT06662669
- Testing
- YL-13027, HY-0102, Gemcitabine
- Volunteers
- 120 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Breast Cancer, Prostate Cancer
Holistic Acupuncture for Patients With Chemotherapy Induced Nausea
The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Gynaecologic Cancer
- Trial name
- NCT07201194
- Testing
- Holistic acupuncture and acupressure, Standard medical treatment
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Vejle Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.